irbesartan

(redirected from Avapro)
Also found in: Medical.
Related to Avapro: irbesartan

ir·be·sar·tan

 (ĭr′bə-sär′tn)
n.
An angiotensin II receptor blocker drug, C25H28 N6O, used to treat hypertension.

[irbe-, origin unknown + -sartan, angiotensin II receptor blocker suff.; see losartan.]
Translations

irbesartan

n irbesartán m
References in periodicals archive ?
Irbesartan Tablets USP 75mg, 150mg and 300mg are therapeutically equivalent to Avapro Tablets, 75mg, 150mg and 300 mg of Sanofi-aventis U.
But the hypertension market growth will be countered by significant drug patent expirations both prior to and during the forecast period, including those of Cozaar in 2010, Diovan, Avapro and Atacand in 2012, Exforge in 2014, Benicar in 2016, and Tekturna and Tekturna HCT in 2018.
88bn, as the company's Avapro blood pressure drug and Plavix blood clot preventer faced competition from cheaper generics.
The medicines to be distributed include Plavix, Avapro and Meformin.
Blood pressure drugs Avapro and Avalide, which lost patent protection last March, dropped 57 percent to $84 million.
M2 PHARMA-October 15, 2012-Watson Pharmaceuticals Inc to launch generic Avapro today following FDA approval(C)2012 M2 COMMUNICATIONS
M2 EQUITYBITES-October 15, 2012-Watson Pharmaceuticals Inc to launch generic Avapro today following FDA approval(C)2012 M2 COMMUNICATIONS http://www.
Such a move holds the promise of giving consumers access to chronic-condition drugs such as Avapro, Diovan and Atacand for hypertension; Lescol and Tricor for hyperlipidemia; Maxalt and Zomig for migraine; and Singulair and Xopenex for asthma.
While Moody's is upbeat about the ongoing launch of Bristol's Yervoy therapy and the pending regulatory filing for its Eliquis medication, it voiced concerns over a potential sharp decline in revenues when Plavix and Avapro go off-patent in the United States.
Other lots of Avalide 300/25 mg, as well as other dosage strengths of both Avalide and Avapro, or irbesartan, are not affected, and no interruption in supply is anticipated, the company said.
Also, supported by sales of new products Lonasen (agent for the treatment of schizophrenia) and Avapro (agent for the treatment of hypertension), sales grew by JPY 4.
Also at risk is anyone on a medication that causes the body to hold onto potassium, including potassium-sparing diuretics like Dyazide and Spirozide, ACE inhibitors like Lotensin and Vasotec, angiotensin-receptor blockers such as Tevetan and Avapro and daily doses of nonsteroidal anti-inflammatory drugs like aspirin and ibuprofen.